Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza, Pandemic Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

NCT00771615
View directory record Official record
Conditions
Influenza
Interventions
GSK A/turkey H5N1 Influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00952276
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Anaheim, California • Fountain Valley, California • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

NCT05422326
View directory record Official record
Conditions
Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections, Orthomyxoviridae Infections, RNA Virus Infections, Virus Diseases, Respiratory Tract Diseases
Interventions
aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
18
States / cities
Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

NCT00989404
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype
Interventions
Zanamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

NCT01674205
View directory record Official record
Conditions
Influenza, Human
Interventions
A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®), Vaccine placebo (Leibovitz-15 [L-15]), Vaccine placebo (FluMist®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® 2009-2010 Formula, FluMist® 2009-2010 Formula
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

NCT00519389
View directory record Official record
Conditions
Pandemic Influenza
Interventions
H5N1 VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
View directory record Official record
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 27, 2026, 1:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511
View directory record Official record
Conditions
Pandemic Influenza Immunization, Healthy Volunteers
Interventions
Pandemic flu H5 HA mRNA SD2 vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
13
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 27, 2026, 1:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926
View directory record Official record
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

NCT01766921
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
1,393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Hollywood, Florida • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00853255
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 27, 2026, 1:10 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

NCT07496450
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1018-H5, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
10
States / cities
San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

NCT00310206
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

NCT06382311
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Influenza virus vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
991 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
21
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 27, 2026, 1:10 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

NCT01032837
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
100
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Dose Ranging Study With Adjuvant Patch

NCT00532792
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 27, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

NCT01594320
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 27, 2026, 1:10 AM EDT